SEHK:1099Healthcare
Sinopharm Group (SEHK:1099) Q1 Net Margin Of 1.6% Tests Thin Profit Narrative
Sinopharm Group (SEHK:1099) opened 2026 with Q1 revenue of about CNY 17.8b and basic EPS of CNY 0.52, setting the tone against a trailing twelve month profile that shows revenue of roughly CNY 574.7b and EPS of CNY 2.28. Over recent quarters investors have seen quarterly revenue move from about CNY 141.7b in Q1 2025 to CNY 145.4b in Q3 2025 and CNY 143.7b in Q4 2025, with basic EPS ranging from CNY 0.47 to CNY 3.29 across that period as the business cycled through different earnings levels...